Li M, Lionikas A, Yu F, Tajsharghi H, Oldfors A, Larsson L
Department of Clinical Neurophysiology, Uppsala University, Uppsala SE-75185, Sweden.
Neuromuscul Disord. 2006 Nov;16(11):782-91. doi: 10.1016/j.nmd.2006.07.023. Epub 2006 Sep 26.
The pathogenic events leading to the progressive muscle weakness in patients with a E706K mutation in the head of the myosin heavy chain (MyHC) IIa were analyzed at the muscle cell and motor protein levels. Contractile properties were measured in single muscle fiber segments using the skinned fiber preparation and a single muscle fiber in vitro motility assay. A dramatic impairment in the function of the IIa MyHC isoform was observed at the motor protein level. At the single muscle fiber level, on the other hand, a general decrease was observed in the number of preparations where the specific criteria for acceptance were fulfilled irrespective of MyHC isoform expression. Our results provide evidence that the pathogenesis of the MyHC IIa E706K myopathy involves defective function of the mutated myosin as well as alterations in the structural integrity of all muscle cells irrespective of MyHC isoform expression.
在肌球蛋白重链(MyHC)IIa头部存在E706K突变的患者中,导致进行性肌肉无力的致病事件在肌肉细胞和运动蛋白水平进行了分析。使用去皮肤纤维制备和单根肌纤维体外运动分析,在单根肌纤维节段中测量收缩特性。在运动蛋白水平观察到IIa MyHC同工型功能的显著损害。另一方面,在单根肌纤维水平,无论MyHC同工型表达如何,满足特定接受标准的制备物数量普遍减少。我们的结果提供了证据,表明MyHC IIa E706K肌病的发病机制涉及突变肌球蛋白的功能缺陷以及所有肌肉细胞结构完整性的改变,而与MyHC同工型表达无关。